Inovio Pharmaceuticals, Inc. (INO) - NASDAQ
  • Mon, May 9, 8:59 AM
    • Inovio Pharmaceuticals (INO) Q1 results: Revenues: $8.1M (+55.8%); R&D Expense: $18.2M (+93.6%); SG&A: $5.4M (+31.7%); Operating Loss: ($15.5M) (-84.5%); Net Loss: ($8M) (+24.5%); Loss Per Share: ($0.11) (+38.9%); Quick Assets: $146.8M (-9.9%); CF Ops: ($15.7M) (-29.8%).
    • No guidance given.
    | Mon, May 9, 8:59 AM
  • Mon, May 9, 6:59 AM
    • Inovio Pharmaceuticals (NASDAQ:INO): Q1 EPS of -$0.11 beats by $0.03.
    • Revenue of $8.11M (+56.9% Y/Y) beats by $3.36M.
    • Press Release
    | Mon, May 9, 6:59 AM | 1 Comment
  • Mon, Mar. 14, 6:55 AM
    • Inovio Pharmaceuticals (INO) Q4 results: Revenues: $5.9M (+136.0%); R&D Expense: $15.6M (+69.6%); SG&A: $4.9M (+16.7%); Net Loss: ($18M) (-143.2%); Loss Per Share: ($0.25) (-108.3%).
    • FY2015 results: Revenues: $40.6M (+286.7%); R&D Expense: $57.8M (+69.5%); SG&A: $18.1M (+13.8%); Operating Loss: ($34.3M) (+13.2%); Net Loss: ($29.2M) (+19.1%); Loss Per Share: ($0.44) (+31.3%); Quick Assets: $163M (+74.1%).
    • No guidance given.
    | Mon, Mar. 14, 6:55 AM
  • Mon, Mar. 14, 6:31 AM
    • Inovio Pharmaceuticals (NASDAQ:INO): Q4 EPS of -$0.25 misses by $0.05.
    • Revenue of $5.9M (+139.8% Y/Y) misses by $1.06M.
    • Press Release
    | Mon, Mar. 14, 6:31 AM
  • Nov. 9, 2015, 9:51 AM
    • Inovio Pharmaceuticals (INO -0.07%) Q3 results: Revenues: $24.2M (+999%); R&D Expense: $16.1M (+130.0%); SG&A: $4.4M (+37.5%); Operating Income: $3.7M (+144.6%); Net Income: $5.6M (+177.8%); EPS: $0.07 (+158.3%); Quick Assets: $170.8M (+82.5%).
    • No guidance given.
    | Nov. 9, 2015, 9:51 AM
  • Nov. 9, 2015, 7:05 AM
    • Inovio Pharmaceuticals (NASDAQ:INO): Q3 EPS of $0.07 beats by $0.03.
    • Revenue of $24.18M (+1214.1% Y/Y) in-line.
    | Nov. 9, 2015, 7:05 AM | 1 Comment
  • Aug. 10, 2015, 7:30 AM
    • Inovio Pharmaceuticals (INO -4.6%) Q2 results: Revenues: $5.3M (+39.5%); R&D Expense: $16.7M (+74.0%); SG&A: $4.7M (+9.3%); Operating Loss: ($15.1M) (-48.0%); Net Loss: ($6.2M) (+42.1%); Loss Per Share: ($0.09) (+52.6%); Quick Assets: $154.6M (+65.2%).
    • No guidance given.
    | Aug. 10, 2015, 7:30 AM | 2 Comments
  • Aug. 10, 2015, 6:12 AM
    • Inovio Pharmaceuticals (NASDAQ:INO): Q2 EPS of -$0.09 beats by $0.04.
    • Revenue of $5.3M (+39.5% Y/Y) misses by $0.22M.
    • Shares +9.4% PM.
    | Aug. 10, 2015, 6:12 AM | 1 Comment
  • May 11, 2015, 9:09 AM
    • Inovio Pharmaceuticals (INO -0.9%) Q1 results: Revenues: $5.2M (+116.7%); R&D Expense: $9.4M (+14.6%); SG&A: $4.1M (-0.7%); Operating Loss: ($8.4M) (+16.0%); Net Loss: ($10.6M) (+1.9%); Loss Per Share: ($0.18) (+10.0%); Quick Assets: $81M (-13.5%).
    • No guidance given.
    | May 11, 2015, 9:09 AM
  • May 11, 2015, 7:02 AM
    • Inovio Pharmaceuticals (NASDAQ:INO): Q1 EPS of -$0.18 misses by $0.07.
    • Revenue of $5.17M (+119.1% Y/Y) misses by $1.87M.
    | May 11, 2015, 7:02 AM
  • Mar. 16, 2015, 7:50 AM
    • Inovio Pharmaceuticals (INO -3.6%) Q4 results: Revenues: $2.5M (+47.1%); R&D Expense: $9.2M (+43.8%); SG&A: $4.2M (-2.3%); Net Loss: ($7.4M) (+52.3%); Loss Per Share: ($0.12) (+60.0%).
    • FY2014 results: Revenues: $10.5M (-22.2%); R&D Expense: $34.1M (+59.3%); SG&A: $15.9M (+16.9%); Operating Loss: ($39.5M) (-102.6%); Net Loss: ($36.1M) (+45.3%); Loss Per Share: ($0.64) (+55.2%); Quick Assets: $93.6M (+77.9%).
    • No guidance given.
    | Mar. 16, 2015, 7:50 AM | 1 Comment
  • Mar. 16, 2015, 6:43 AM
    • Inovio Pharmaceuticals (NASDAQ:INO): Q4 EPS of -$0.12 misses by $0.02.
    • Revenue of $2.5M (+43.7% Y/Y) misses by $2.74M.
    | Mar. 16, 2015, 6:43 AM
  • Nov. 10, 2014, 11:06 AM
    • Inovio Pharmaceuticals (INO -4.3%) Q3 results: Revenues: $1.8M (-81.1%); R&D Expense: $7M (+29.6%); G&A: $3.2M (-3.0%); Operating Loss: ($8.3M) (-999%); Net Loss: ($7.2M) (+76.7%); Loss Per Share: ($0.12) (+81.3%); Quick Assets: $100.9M (+91.5%).
    • No guidance given.
    | Nov. 10, 2014, 11:06 AM
  • Nov. 10, 2014, 6:59 AM
    • Inovio Pharmaceuticals (NASDAQ:INO): Q3 EPS of -$0.12 beats by $0.02.
    • Revenue of $1.8M (-81.0% Y/Y) misses by $3.78M.
    | Nov. 10, 2014, 6:59 AM
  • Nov. 4, 2014, 11:57 AM
    • Inovio Pharmaceuticals (INO -2.1%) will report Q3 results on November 10 before the open. The conference call will begin at 8:00 am ET.
    • Consensus view is a loss of ($0.14) on revenues of $5.6M.
    | Nov. 4, 2014, 11:57 AM
Company Description
Inovio Pharmaceuticals, Inc. is revolutionizing the fight against cancer and infectious diseases. Its immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. With an expanding... More
Sector: Healthcare
Industry: Biotechnology
Country: United States